A California tech company is planning on rolling out a handful of atmospheric water generation projects near Houston. Photo via skyh2o.com

Houstonians are used to filtering their water, but few really ponder why they’re doing it.

“Most people, when they think about water stress, they think about water scarcity, like what you see happening in Northern Africa or maybe the Southern U.S.,” says Alexander von Welczeck, chairman, president and CEO of SkyH2O. “A bigger, creeping issue, particularly in the industrialized world, is water toxicity.”

Some Houston tap water contains “forever chemicals” that can be toxic, as some reports have found. In fact, says von Welczeck, water toxicity is a problem across the Gulf Coast. That’s why the California-based businessman has identified Houston as the first region to benefit from SkyH2O’s technology.

The company will break ground on its first SkyH2O Station in the first quarter of 2024 in Dickinson, strategically placed between Houston and Galveston. That will be followed by another in Angleton. Eventually, says von Welczeck, there will be eight SkyH2O stations in the greater Houston area.

Von Welczek describes a SkyH2O Station as bearing a resemblance to “a big, modern gas station, but as opposed to gas, the primary product is fresh, healthy water.” With everything from charging stations for electric vehicles to a farmers market-style set-up of sustainable food, the stations will indeed be like a futuristic gas station.

Water will be distributed both in recyclable packaging for smaller businesses and homes, and in bulk to fill water tankers for ranches and other larger customers. Von Welczeck foresees, for example, Galveston cruise ships filling up with a supply of water at that station.

But where will this fresh, clean water come from? SkyH2O uses atmospheric water generation, or AWG, systems to pull humidity from the air and turn it into potable water. The higher the humidity, the more water can be produced.

“Obviously in and around Houston, we have tremendous humidity,” von Welczeck says.

This is all done using the Maximus 4260, the latest and greatest of the company’s AWG systems. The machine is rated to produce 10,500 litres of fresh, potable water a day. It produces net zero water, meaning that it doesn’t come from any existing water resource.

What comes out initially is a semi-distilled, purified water. The next step is further filtering it and adding minerals to make the product potable for customers. Von Welczeck says that SkyH2O’s water meets the Texas Commission on Environmental Quality’s water standards.

The serial entrepreneur has been working in the climate tech space since 2002 and has a proven track record. Von Welczeck says that he sold his company, Solar Power Partners, to NRG in 2010.

“From my perspective, most everything in climate technology, whether it's clean energy, recycling, even food and water, they're all interrelated,” he says.

After opening around 20 Texas locations, von Welczeck has his sights set on covering the entire Gulf Coast. After that, he hopes to expand to Mediterranean Europe, particularly water-strapped islands. He’s even in discussions with potential clients in the Middle East. But Houston will be the first to taste SkyH2O’s potentially globe-altering water.

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”